Clinical trials
Adenocarcinoma of Lung trials in France
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
22 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2005 | 1 |
| 2011 | 2 |
| 2012 | 3 |
| 2013 | 3 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 11 |
| Unknown status | 5 |
| Terminated | 4 |
| Active, not recruiting | 1 |
| Recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 8 |
| Central Hospital, Nancy, France | 2 |
| European Organisation for Research and Treatment of Cancer - EORTC | 2 |
| GERCOR - Multidisciplinary Oncology Cooperative Group | 2 |
| Amgen | 1 |
| Bayer | 1 |
| Gustave Roussy, Cancer Campus, Grand Paris | 1 |
| Hospices Civils de Lyon | 1 |
| Institut Bergonié | 1 |
| Turning Point Therapeutics, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Adenocarcinoma of Lung | 22 |
| Carcinoma, Non-Small-Cell Lung | 16 |
| Lung Neoplasms | 16 |
| Neoplasm Metastasis | 3 |
| Neoplasms | 3 |
| Adenocarcinoma, Bronchiolo-Alveolar | 2 |
| Triple Negative Breast Neoplasms | 2 |
| Adenocarcinoma | 1 |
| Breast Neoplasms | 1 |
| Carcinoma, Ductal | 1 |
Trials
Showing 1 to 22 of 22. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.